In today’s briefing:
- EOFLOW/Medtronic Tender: Insulet’s US Complaint Materially Increases Deal Break Risks
- What Is KDB’s Plan B for Asiana Airlines?
EOFLOW/Medtronic Tender: Insulet’s US Complaint Materially Increases Deal Break Risks
- Insulet Corp (PODD US) filed with the United States District Court a complaint for patent infringement against Eoflow (294090 KS), Flex (FLEX US), Luis Malave, Steven DiIanni, and Ian Welsford.
- Insulet’s primary allegation is that Eoflow’s EOPatch device is built using Insulet’s proprietary trade secrets and infringes three Insulet US patents (‘741, ’883 and ‘950 patents).
- The most likely scenarios are that Medtronic Plc (MDT US) and Insulet sign a licensing agreement (resulting in a possible tender offer price cut) or Medtronic walks.
What Is KDB’s Plan B for Asiana Airlines?
- There have been increasing local news flows about KDB’s potential “Plan B” for Asiana Airlines in case the merger between Asiana Airlines and Korean Air Lines is finally cancelled.
- The final decisions by the European and US regulators on whether to pass/block this merger are likely to take place in 4Q 2023.
- The higher probability scenarios are for one or both of these regulators to block this deal. As such, KDB will need to come up with Plan B.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
